Skip to content

Carbetocin approval meeting with FDA

Levo Therapeutic’s New Drug Application (NDA) for Carbetocin as a treatment for PWS has been scheduled for a public meeting of the Psychopharmacologic Drugs Advisory Committee to be held on November 4th, 2021.

DCCR extension results

long term data further demonstrate that DCCR significantly reduced hyperphagia, as well as improved body composition, behaviors, and endocrine and metabolic measures over 52 weeks


Carbetocin, a drug developed by Levo Therapeutics, achieves statistically significant results in the treatment of hyperphagia following a phase 3 trial.

Phase 3 DCCR trial top line results

Top line phase 3 results for DCCR, a drug to treat hyperphagia, shows statistically significant improvements in hyperphagia for patients with severe symptoms. It also saw a significant reduction in body fat mass. Studies will continue to evaluate this promising drug.